Tag: delivery

As Consumer Demand Surges for Lab-Tested Botanical Products, Super Speciosa Responds With a Timely Tincture Update and GMP-Backed Transparency

Buffalo, NY, July 25, 2025 (GLOBE NEWSWIRE) -- POP Biotechnologies (POP BIO), a biotechnology company specializing in nanoparticle-based vaccines, and the Coalition for Epidemic Preparedness Innovations (CEPI) have announced a new collaboration to accelerate the development of vaccines against future pandemic threats, including a potential ‘Disease X’. Backed by up to $1.5 million in funding from CEPI, the partnership will advance POP BIO’s SNAP™ (Spontaneous Nanoliposome Antigen Particleization) platform—a plug-and-play technology designed to enable rapid-response vaccine development through streamlined protein purification and nanoparticle delivery.

KUALA LUMPUR, Malaysia, July 25, 2025 (GLOBE NEWSWIRE) -- Sagtec Global Limited (NASDAQ: SAGT) (“Sagtec” or the “Company”), a provider of enterprise software solutions for high-growth verticals, today announced the successful delivery of the first phase of its previously disclosed US$10 million smart hospitality contract in the United Arab Emirates (UAE), in partnership with SMD Tech – FZCO. The Company has received the first milestone payment, validating both project execution and commercial delivery.

MADRID, 25 July 2025 – Neinor Homes (“Neinor”) (HOME SM), the leading residential platform in Spain, has announced its results for the first half of 2025, confirming the continued growth of its Asset Management business, solid operating margins, and a record commercialization activity. The period also marks an acceleration in the Company’s investment strategy with the launch of a voluntary tender offer for 100% of Aedas Homes’ capital.

Stage 2 Will Introduce Price Increase and APY Adjustment as Project Prepares for Solana Deployment and AI-Driven Governance Rollout

NEW YORK and MAINZ, GERMANY, July 25, 2025 — Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) announced today that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended marketing authorization for the companies’ LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY^® LP.8.1) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals 6 months of age and older. The adaptation is based on the recommendation from the EMA’s Emergency Task Force (ETF) to update COVID-19 vaccines to target the LP.8.1 variant for the 2025-2026 season. The ETF stated that “targeting LP.8.1 will help maintain the effectiveness of the vaccines as SARS-CoV-2 continues to evolve.”²